Ucińska Romana, Damps-Konstańska Iwona, Siemińska Alicja, Jassem Ewa
Gdański Uniwersytet Medyczny, ul. Dębinki 7, Gdańsk.
Pneumonol Alergol Pol. 2012;80(2):140-5.
For the past several years the number of women suffering from chronic obstructive pulmonary disease (COPD) has been steadily increasing. This fact prompts the debate which factors, in addition to considerably increasing prevalence of cigarette smoking among young women, are responsible for these epidemiologic changes. Differences in the natural history and prognosis of COPD in females and males are presented in the paper, as well as the number of potential ethiopathogenetic and pathophysiologic factors influencing these variations. Among them, differences in the COPD risk factors spectrum in both genders and in airways anatomy are pointed out, and the mechanisms responsible for greater women's susceptibility to components of cigarette smoke, which reflect genetic (enzyme polymorphisms), epigenetic (diminished DNA methylation) and hormonal (estrogens) influences on xenobiotics metabolism. Further, sex-related differences regarding COPD phenotypes (chronic bronchitis vs. emphysema), immunological markers and clinical manifestation of disease are underlined in the paper. More frequent coexistence of anxiety and depression, COPD exacerbations and worse quality of life in women are also emphasized. Other differences, pointed out by authors include autoimmunological conception of pathogenesis of COPD (greater female susceptibility to produce autoantibodies), risk factors of disease exacerbation and, at last, response to certain forms of COPD treatment (nicotine replacement therapy, long-term oxygen therapy).
在过去几年中,患有慢性阻塞性肺疾病(COPD)的女性人数一直在稳步增加。这一事实引发了一场争论,即除了年轻女性吸烟率大幅上升之外,还有哪些因素导致了这些流行病学变化。本文介绍了COPD在女性和男性中的自然史和预后差异,以及影响这些差异的潜在病因和病理生理因素的数量。其中,指出了两性COPD危险因素谱和气道解剖结构的差异,以及女性对香烟烟雾成分易感性更高的机制,这反映了遗传(酶多态性)、表观遗传(DNA甲基化减少)和激素(雌激素)对异生物代谢的影响。此外,本文还强调了COPD表型(慢性支气管炎与肺气肿)、免疫标志物和疾病临床表现方面的性别差异。还强调了女性更频繁地同时存在焦虑和抑郁、COPD急性加重以及生活质量较差的情况。作者指出的其他差异包括COPD发病机制的自身免疫概念(女性产生自身抗体的易感性更高)、疾病加重的危险因素,以及最后对某些形式的COPD治疗(尼古丁替代疗法、长期氧疗)的反应。